Antengene
Help people with cancer
live longer and better.
About us

About Us

Management Team


John Z. Gong,

John Z. Gong, M.D., Ph.D

Chairman and CEO

— US FDA Reviewer for 10 years, conducted primary and critical reviews of numerous IND and NDA applications for both small molecules and biologics
— VP of Drug Development and Regulatory Affairs of BeiGene, CEO of BL Pharma, and CTO of JOINN Laboratories
— With more than 30 years of global industry and academic experience, Dr. John Gong devoted into new drug R&D in different stakeholders from FDA, CRO to biotech companies. He gained rich experience on following field: leading global new drug development, manufacture and commercialization, the process of identifying, license-in and co-development drug candidates, strategic planning for global development, registration and commercialization, pre-clinical and clinical trial designs, GLP/GCP/GMP regulations, project risk management
— Post-doc research in National Institutes of Health from 1996 to 1998, Ph.D. degree in Toxicology from New York University in 1996 and medical degree from Beijing Medical College in 1984

— Committee member of the Chinese Pharmaceutical Association, Council member of AAALAC, member of editorial board of Chinese Journal of New Drugs, Progress in Pharmaceutical Sciences and DIA advisory committee

  • Dr. LIU Dongfang

    Dr. LIU Dongfang

    Chief Medical Officer

    — Bachelor in Clinical medicine, Peking University School of Medicine; Master's degree, the University of Toledo; Ph.D. in Biological Engineering, MIT

    — Worked for Celgene, Bristol Myers Squibb and Astrazeneca, 20+ years leadership experience in global clinical operations

     

  • Dr. Shen Xiao

    Dr. Shen Xiao

    Chief Strategy Officer

    — Master in Shanghai Jiao Tong University School of Medicine (formerly Shanghai No.2 Medical University); Ph.D. in West Virginia University; Post-doc, Johns Hopkins University and the University of North Carolina

    — Rich and comprehensive experience in new drug review. During his approximately 20-year work in U.S. Food and Drug Administration (FDA), he has been responsible for the various stages of hundreds of reviews for new drugs, and has been in charge of the New Drug Application (NDA) of a dozen new drugs. Also, he has taken charge of or participated in the drafting or formulation of several FDA guidances on new drug development

  • ZHANG Jing

    ZHANG Jing / USCPA

    Chief Finance Officer

    — Bachelor in Medicine, Sun Yat-sen University; Master in Accountancy, University of South Carolina

    — Member of AICPA, worked for United Technologies and Anthem, 20+ years as global healthcare financial management executive in US MNC, health insurance company and big 4 audit firms

  • XIA Fang

    XIA Fang

    Secretary to the Board, Registration

    — Master in Pharmacognosy, Peking University School of Medicine

    — Worked as deputy director of product design center in Taiji Group in Beijing, responsible for product registration and regulatory communication, 15 years' experience in drug registration

  • Dr. MENG Chuncai

    Dr. MENG Chuncai

    Senior Vice President, General Counsel

    —Bachelor in Law, Beijing Foreign Affairs University; Master in Law, Edinburgh University; Juris Doctor,Ohio State University
    —Nearly 30 years of law related work experience, with rich experience in general legal practice,legal risk control, compliance and legal team management. Served as vice president of legal affairs in Lenovo Group, as well as General Counsel and Chief Compliance Officer in Novartis China and SciClone Pharm

  • Dr. LIN Yihui

    Dr. LIN Yihui

    Vice President, Translational Medicine Center

    — Ph.D. in Biology, Center for Excellence in Molecular Cell Science, CAS

    — Worked for GlaxoSmithKline and the Institute of Health Sciences, experienced in biomarker validation and translational medicine

  • ZHU Ming

    ZHU Ming

    Vice President, Government Affair and Public Relation

    — Bachelor in Finance, Suzhou University

    — Previous experience in WuXi AppTec, JOINN Laboratories and BL Pharma, 17 years operation management experience

  • HE Yue

    HE Yue

    Senior Director, Quality Management

    — Master in Clinical Medicine, West China Hospital, Sichuan University

    — Worked for BeiGene, Biotech Pharma and Tong-yang Pharmaceuticals, 17 years' clinical research experience

  • Dr. WEI Guoping

    Dr. WEI Guoping

    Vice President, Medicinal Chemistry

    — Ph.D. in Organic Chemistry, Chinese Academy of Sciences; Post-doc, The Ohio State University; Post-doc, University of California, Riverside

    — Worked for Pharmaron, Wuxi AppTec, Acme Bioscience, and Berlex Biosciences, 20 years’ experience in drug discovery and development in medicinal chemistry

    — Productive research results: 2 clinical candidate drugs 10 pre-clinical candidate drugs

  • Dr. ZHOU Jian

    Dr. ZHOU Jian

    Vice President, Small Molecule CMC

    — Master in Medicinal Chemistry, Peking University; Ph.D in Bioorganic Chemistry, University College Dublin, Ireland; Post-doc, National University of Ireland-Galway, Ireland

    — Comprehensive experience in drug R & D, manufacturing, quality research and the construction of pharmaceutical plants

     

  • Dr. FENG Qiang

    Dr. FENG Qiang

    Senior Director, Biopharmaceutical CMC

    — Bachelor of Pharmacy, Xi'an Jiaotong University, Master and Ph.D in Cell Biology, Fourth Military Medical University

    — Worked for the Fourth Military Medical University, Jiangsu Pacific Minox, CANbridge, Henlius and other universities and pharmaceutical enterprises, and his working experience covers different stages of drug R & D and production. Published a number of SCI papers, obtained a number of patents, and undertaken or participated in a number of national key scientific research projects

  • Dr. LIU Dongfang

    Dr. LIU Dongfang

    Chief Medical Officer

    — Bachelor in Clinical medicine, Peking University School of Medicine; Master’s degree, the University of Toledo; Ph.D. in Biological Engineering, MIT

    — Worked for Celgene, Bristol Myers Squibb and Astrazeneca, 20+ years leadership experience in global clinical operations

  • Dr. Shen Xiao

    Dr. Shen Xiao

    Chief Strategy Officer

    — Master in Shanghai Jiao Tong University School of Medicine (formerly Shanghai No.2 Medical University); Ph.D. in West Virginia University; Post-doc, Johns Hopkins University and the University of North Carolina

    — Rich and comprehensive experience in new drug review. During his approximately 20-year work in U.S. Food and Drug Administration (FDA), he has been responsible for the various stages of hundreds of reviews for new drugs, and has been in charge of the New Drug Application (NDA) of a dozen new drugs. Also, he has taken charge of or participated in the drafting or formulation of several FDA guidances on new drug development

  • ZHANG Jing

    ZHANG Jing / USCPA

    Chief Finance Officer

    — Bachelor in Medicine, Sun Yat-sen University; Master in Accountancy, University of South Carolina

    — Member of AICPA, worked for United Technologies and Anthem, 20+ years as global healthcare financial management executive in US MNC, health insurance company and big 4 audit firms

  • XIA Fang

    XIA Fang

    Secretary to the Board, Registration

    — Master in Pharmacognosy, Peking University School of Medicine

    — Worked as deputy director of product design center in Taiji Group in Beijing, responsible for product registration and regulatory communication, 15 years' experience in drug registration

     

  • Dr. MENG Chuncai

    Dr. MENG Chuncai

    Senior Vice President, General Counsel

    — Bachelor in Law, Beijing Foreign Affairs University; Master in Law, Edinburgh University; Juris Doctor, Ohio State University
    — Nearly 30 years of law related work experience, with rich experience in general  legal practice,legal risk control, compliance  and legal team management. Served as vice president of legal affairs in Lenovo Group, as well as General Counsel and Chief Compliance Officer in Novartis China and SciClone Pharm

  • Dr. LIN Yihui

    Dr. LIN Yihui

    Vice President, Translational Medicine Center

    — Ph.D. in Biology, Center for Excellence in Molecular Cell Science, CAS

    — Worked for GlaxoSmithKline and the Institute of Health Sciences, experienced in biomarker validation and translational medicine

     

  • ZHU Ming

    ZHU Ming

    Vice President, Government Affair and Public Relation

    — Bachelor in Finance, Suzhou University

    — Previous experience in WuXi AppTec, JOINN Laboratories and BL Pharma, 17 years operation management experience

     

  • HE Yue

    HE Yue

    Senior Director, Quality Management

    — Master in Clinical Medicine, West China Hospital, Sichuan University

    — Worked for BeiGene, Biotech Pharma and Tong-yang Pharmaceuticals, 17 years' clinical research experience

  • Dr. WEI Guoping

    Dr. WEI Guoping

    Vice President, Medicinal Chemistry

    — Ph.D. in Organic Chemistry, Chinese Academy of Sciences; Post-doc, The Ohio State University; Post-doc, University of California, Riverside

    — Worked for Pharmaron, Wuxi AppTec, Acme Bioscience, and Berlex Biosciences, 20 years' experience in drug discovery and development in medicinal chemistry

    — Productive research results: 2 clinical candidate drugs 10 pre-clinical candidate drugs

  • Dr. ZHOU Jian

    Dr. ZHOU Jian

    Vice President, Small Molecule CMC

    — Master in Medicinal Chemistry, Peking University; Ph.D in Bioorganic Chemistry, University College Dublin, Ireland; Post-doc, National University of Ireland-Galway, Ireland
    — Comprehensive experience in drug R & D, manufacturing, quality research and the construction of pharmaceutical plants

  • Dr. FENG Qiang

    Dr. FENG Qiang

    Senior Director, Biopharmaceutical CMC

    — Bachelor of Pharmacy, Xi'an Jiaotong University, Master and Ph.D in Cell Biology, Fourth Military Medical University

    — Worked for the Fourth Military Medical University, Jiangsu Pacific Minox, CANbridge, Henlius and other universities and pharmaceutical enterprises, and his working experience covers different stages of drug R & D and production. Published a number of SCI papers, obtained a number of patents, and undertaken or participated in a number of national key scientific research projects.